Absorption, Metabolism, Distribution and Excretion (ADME) and Absolute Bioavailability Assessment of Zongertinib in Healthy Male Volunteers
Open Access
- 5 December 2025
- journal article
- research article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 46 (2) , 115-125
Abstract
Background and Objectives Zongertinib is an irreversible tyrosine kinase inhibitor that selectively inhibits human epidermal growth factor receptor 2 (HER2) while sparing epidermal growth factor receptor (EGFR), minimizing related toxicities. This non-randomized, open-label, Phase I study evaluated the absorption, distribution, metabolism and excretion (ADME) of zongertinib (Part A) and its absolute bioavailability (F) (Part B) in healthy male volunteers. Methods In Part A, eight subjects received a single oral 60 mg dose of zongertinib (C-14)-solution containing radiolabeled [14C]zongertinib [3.7 MBq] and unlabeled drug. In Part B, seven subjects received an oral unlabeled zongertinib 60-mg film-coated tablet after fasting, followed by a 15-min intravenous (IV) infusion of 100 μg zongertinib solution (C-14), consisting of 10 μg [14C]zongertinib [~ 0.03 MBq] and 90 μg unlabeled drug. Plasma pharmacokinetics, excretion pathways, metabolism, and bioavailability were assessed. Safety was evaluated in both study parts. Results After oral dosing in Part A, peak plasma concentration occurred at a median of 1-h post-dose (range 0.5‒2.0 h). Mean recovery of the radioactive dose was 93.8%, primarily in feces (92.5%) and minimally in urine (1.30%). Unchanged zongertinib accounted for most circulating radioactivity (74.6%) in plasma and was the most abundant component in feces (31.4% of the dose) and urine (0.18% of dose). In vitro metabolism involved oxidation (48–62%), glucuronidation (13–25%), and glutathione conjugation (13–25%). In part B, the mean F of the oral tablet was 76.2%. Following IV administration, zongertinib showed low plasma clearance (106 mL/min) and a moderate volume of distribution of 138 L. Zongertinib had a manageable safety profile in both study parts. Conclusions Zongertinib was rapidly absorbed with high absolute bioavailability. The unchanged zongertinib was the predominant form in plasma and excreta, with fecal excretion as the main elimination pathway. Metabolism occurred primarily through oxidation, with minor contributions from glucuronidation and glutathione conjugation. Clinical Trial Registration Registered under identifier NCT05879991 (25 May 2023).Keywords
Funding Information
- Boehringer Ingelheim
This publication has 20 references indexed in Scilit:
- 2025 CPDD Abstract BookletClinical Pharmacology in Drug Development, 2025
- Non-small-cell lung cancerNature Reviews Disease Primers, 2024
- HER2-targeted therapies beyond breast cancer — an updateNature Reviews Clinical Oncology, 2024
- Novel therapeutic strategies for rare mutations in non-small cell lung cancerScientific Reports, 2024
- Targeting HER2 alterations in non-small cell lung cancer: Therapeutic breakthrough and challengesCancer Treatment Reviews, 2023
- A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 AberrationsClinical Lung Cancer, 2022
- Mini‐Review: Comprehensive Drug Disposition Knowledge Generated in the Modern Human Radiolabeled ADME StudyCPT: Pharmacometrics & Systems Pharmacology, 2020
- Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLCCritical Reviews in Oncology/Hematology, 2020
- Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancerNature Medicine, 2018
- Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteersCancer Chemotherapy and Pharmacology, 2011